IndustryCompany release
Psyence Biomedical adds ibogaine for opioid use disorder via new Texas subsidiary
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026
The psychedelic drug developer reports a six-month net loss of $1.94M and cash of $21.1M, while its psilocybin Phase IIb trial continues in Australia.
Psyence Biomedical has set up Texas Ibogaine Research Corporation and signed a binding term sheet for a U.S. licence to PsyLabs' ibogaine hydrochloride, with opioid use disorder as the target indication. The move was disclosed in the company's management discussion and analysis (MD&A) for the six months to 30 September 2026, dated 19 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Psyence Biomedical Ltd. ↗
Article written by VigiEye from the official source (Psyence Biomedical Ltd.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Brainstorm Cell proposes governance reforms to settle NurOwn derivative suits, with $725,000 in fees
🇺🇸 Brainstorm Cell Therapeutics Inc. (BCLI) · Fri 20 Nov 2026
Scienture Q3 revenue reaches $1.25M as REZENOPY naloxone nasal spray launches
🇺🇸 Scienture Holdings, Inc. (SCNX) · Thu 19 Nov 2026
Medicus Pharma regains Nasdaq equity compliance after equity raise and debt-for-preferred swap
🇺🇸 Medicus Pharma Ltd. (MDCX) · Thu 19 Nov 2026
Kazia files FY2026 20-F, reporting A$61.2M cash and early paxalisib breast cancer data
Kazia Therapeutics Ltd (KZIA) · Thu 19 Nov 2026
Psyence Biomedical reports $1.94M half-year loss as equity line lifts cash to $21.1M
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026
CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%
🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026